The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2025 | Differences between the WHO and ICC definitions of T-cell malignancies
Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, highlights differences between the International Consensus Classification (ICC) and World Health Organization (WHO) definitions of T-cell malignancies. She notes differences in the nomenclature and approach to clonal proliferations of T-cells that affect the mucosa of the gastrointestinal tract. This interview took place at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL 2025), held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I must say looking at the two classifications, probably T-cell neoplasm is a group of diseases where the divergences are minimal. I must say. So there are some differences in the nomenclature of some entities, the way for example follicular helper T-cell lymphomas are named is follicular helper T-cell lymphoma in the ICC, in the WHO the prefix nodal is added to stress on the fact those diseases mostly present in lymph nodes...
I must say looking at the two classifications, probably T-cell neoplasm is a group of diseases where the divergences are minimal. I must say. So there are some differences in the nomenclature of some entities, the way for example follicular helper T-cell lymphomas are named is follicular helper T-cell lymphoma in the ICC, in the WHO the prefix nodal is added to stress on the fact those diseases mostly present in lymph nodes. This is to highlight a small difference, but overall there’s good concordance in the number and in the names of the entities. Maybe one additional kind of significant difference, but that applies to a rare group of disorders. It’s the way to approach some proliferations, clonal proliferations of T-cells that affect the mucosa of the gastrointestinal tract. These diseases, as I said, are rare. They mostly affect the mucosa, may not always be mass-forming. And the approach in the ICC is to call these disorders clonal lymphoproliferations, while the WHO calls them indolent lymphomas. And, you know, these definitely will be points that need to be resolved in the next months or hopefully for the next WHO classification.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
